Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03429556 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03429556 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 23 participants.
The verdict
NCT03429556, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of single intra-operative treatment of Botulinum Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA) in participants undergoing abdominoplasty.
Interventions
- DRUG Placebo
- BIOLOGICAL Botulinum Neurotoxin Serotype E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03429556
The ClinicalTrials.gov registry entry for NCT03429556 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03429556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03429556 about?
NCT03429556 is a clinical study titled "Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty". To determine the safety and efficacy of single intra-operative treatment of Botulinum Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA) in participants undergoing abdominoplasty.
What is the current status of trial NCT03429556?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-05-08. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT03429556?
The interventions under investigation include: Placebo (DRUG), Botulinum Neurotoxin Serotype E (BIOLOGICAL).
Who is sponsoring clinical trial NCT03429556?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.